Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Change in Cash: 2022-2025

Historic Change in Cash for bioAffinity Technologies (BIAF) over the last 4 years, with Sep 2025 value amounting to $6.9 million.

  • bioAffinity Technologies' Change in Cash rose 15450.34% to $6.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.9 million, marking a year-over-year increase of 284.21%. This contributed to the annual value of -$1.7 million for FY2024, which is 80.03% up from last year.
  • bioAffinity Technologies' Change in Cash amounted to $6.9 million in Q3 2025, which was up 1,817.29% from $358,129 recorded in Q2 2025.
  • Over the past 5 years, bioAffinity Technologies' Change in Cash peaked at $13.3 million during Q3 2022, and registered a low of -$3.8 million during Q3 2023.
  • For the 3-year period, bioAffinity Technologies' Change in Cash averaged around -$340,415, with its median value being -$660,585 (2025).
  • Its Change in Cash has fluctuated over the past 5 years, first tumbled by 394.48% in 2023, then soared by 15,450.34% in 2025.
  • Over the past 4 years, bioAffinity Technologies' Change in Cash (Quarterly) stood at -$2.1 million in 2022, then climbed by 19.02% to -$1.7 million in 2023, then skyrocketed by 120.66% to $348,711 in 2024, then skyrocketed by 15,450.34% to $6.9 million in 2025.
  • Its Change in Cash stands at $6.9 million for Q3 2025, versus $358,129 for Q2 2025 and -$660,585 for Q1 2025.